Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025
National Post29-06-2025
Article content
ROCKVILLE, Md. & EDMONTON, Alberta — Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that it will host a webcast and conference call on June 30, 2025, at 8:30 a.m. ET to discuss AUR200 Phase 1 study results. The link to the webcast is available here. To join the conference call, please dial 877-407-9170/+1 201-493-6756. Click here for participant International Toll-Free access numbers. A replay of the webcast will be available on Aurinia's website.
Article content
About Aurinia
Article content
Article content
Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS ® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia is also developing AUR200, a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases.
Article content
Article content
Article content
Article content
Article content
Article content
ROCKVILLE, Md. & EDMONTON, Alberta — Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that it will host a webcast and conference call on June 30, 2025, at 8:30 a.m. ET to discuss AUR200 Phase 1 study results. The link to the webcast is available here. To join the conference call, please dial 877-407-9170/+1 201-493-6756. Click here for participant International Toll-Free access numbers. A replay of the webcast will be available on Aurinia's website.
Article content
About Aurinia
Article content
Article content
Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS ® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia is also developing AUR200, a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases.
Article content
Article content
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBC
8 hours ago
- CBC
Want Air Canada to reroute your flight? Prepare for 'turbulence,' says this passenger
Air Canada says it plans to restart flights Monday evening after striking flight attendants defied the federal government's back-to-work order Sunday morning. For Lila Rousseaux, a longtime Air Canada customer, the weekend work stoppage has resulted in inflexibility from the airline as she and her family try to reroute their way home.
CTV News
9 hours ago
- CTV News
‘We're done': Union president on Air Canada flight attendants refusing back to work order
Video CUPE's Air Canada Component President Wesley Lesosky says that the union is 'not willing' to accept the back-to-work order.
CTV News
9 hours ago
- CTV News
Air Canada says they won't resume operations today as strike continues
Watch Planes remained grounded and hundreds more Air Canada flights are cancelled after the union representing flight attendants defied the federal back to work order.
